Johnson Investment Counsel Inc. Has $131,000 Stock Holdings in Evolent Health, Inc. (NYSE:EVH)

Johnson Investment Counsel Inc. grew its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 28.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,607 shares of the technology company’s stock after acquiring an additional 2,542 shares during the period. Johnson Investment Counsel Inc.’s holdings in Evolent Health were worth $131,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in Evolent Health by 12.8% in the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after acquiring an additional 1,426,747 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Evolent Health by 1,948.5% in the third quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock valued at $42,289,000 after purchasing an additional 1,422,385 shares in the last quarter. Bellevue Group AG boosted its position in shares of Evolent Health by 59.9% during the third quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after buying an additional 1,000,215 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Evolent Health by 90.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company’s stock worth $9,036,000 after buying an additional 380,790 shares in the last quarter. Finally, Foundry Partners LLC purchased a new stake in Evolent Health in the 3rd quarter valued at $10,042,000.

Insider Buying and Selling

In related news, President Daniel Joseph Mccarthy bought 11,040 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the completion of the transaction, the president now directly owns 389,004 shares in the company, valued at approximately $3,504,926.04. The trade was a 2.92 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Brendan B. Springstubb purchased 5,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was bought at an average cost of $8.75 per share, with a total value of $43,750.00. Following the completion of the acquisition, the director now directly owns 11,842 shares of the company’s stock, valued at approximately $103,617.50. This trade represents a 73.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 74,000 shares of company stock valued at $666,315. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. UBS Group cut their price objective on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. Citigroup dropped their target price on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. BTIG Research reduced their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, December 3rd. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Evolent Health in a research report on Friday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Evolent Health in a research report on Friday, February 21st. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $17.71.

Evolent Health Stock Down 1.1 %

EVH stock opened at $9.44 on Friday. The stock has a fifty day moving average of $10.22 and a 200-day moving average of $17.17. Evolent Health, Inc. has a fifty-two week low of $8.35 and a fifty-two week high of $33.63. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.51 and a beta of 1.49. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. As a group, equities research analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.